Table 2 Univariate and multivariate analyses
Factors | Univariate analysis | Cox’s proportional hasard model | ||||||
|---|---|---|---|---|---|---|---|---|
Logrank test | 95% CI | |||||||
Cases | Recurrence/died | 10 year RFS (%) | P value | HR | Lower limit | Upper limit | P value | |
Calendar year of surgery | ||||||||
1986–1995 | 80 | 35 | 65.7 | 0.5963 | ||||
1996–2002 | 80 | 32 | 61.0 | |||||
Family history of breast cancer | ||||||||
None | 138 | 58 | 64.9 | 0.9870 | ||||
Positive | 22 | 9 | 56.9 | |||||
Years from the last delivery (YFLC) | ||||||||
Nulliparous | 84 | 42 | 59.4 | 0.1208 | 1 | |||
Recent (<8) | 20 | 9 | 58.7 | 0.731 | 0.317 | 1.686 | 0.4618 | |
Past (≥8) | 56 | 16 | 72.0 | 0.422 | 0.186 | 0.956 | 0.0387 | |
Past | 56 | 16 | 72.0 | 0.0399 | ||||
Nulliparous/Recent | 104 | 51 | 59.3 | |||||
Tumor size, cm (Pathological) | ||||||||
≤5 | 113 | 43 | 67.0 | <0.0001 | 1 | |||
>5 | 17 | 13 | 23.5 | 1.426 | 0.520 | 3.912 | 0.4911 | |
The number of metastatic lymph nodes | ||||||||
None | 78 | 25 | 74.9 | <0.0001 | 1 | |||
1–3 | 47 | 17 | 72.1 | 1.812 | 0.805 | 4.079 | 0.1512 | |
4–9 | 19 | 12 | 36.8 | 3.388 | 1.363 | 8.425 | 0.0086 | |
10– | 15 | 13 | 13.3 | 6.714 | 2.033 | 22.177 | 0.0018 | |
Histological typea | ||||||||
Papillotubular carcinoma | 45 | 10 | 83.7 | 0.0149 | 1 | |||
Sollid-tubular carcinoma | 44 | 19 | 58.2 | 3.348 | 1.352 | 8.292 | 0.0090 | |
Scirrhous carcinoma | 57 | 30 | 55.4 | 2.294 | 1.013 | 5.197 | 0.0465 | |
Special types | 14 | 8 | 50.0 | 2.816 | 0.887 | 8.944 | 0.0791 | |
Extent of tumor invasion (histological) | ||||||||
Localized within gland or fat | 149 | 60 | 65.7 | 0.0072 | 1 | |||
Invading the skin and/or muscle | 11 | 7 | 36.4 | 2.455 | 0.888 | 6.787 | 0.0834 | |
Lymphovascular invasion | ||||||||
Absent | 98 | 33 | 71.7 | 0.0015 | 1 | |||
Present | 62 | 34 | 50.6 | 1.883 | 0.966 | 3.696 | 0.0629 | |
Estrogen receptor(EIA), fmol/mg | ||||||||
<5 (negative) | 61 | 28 | 62.9 | 0.3093 | ||||
5–21 (weakly positive) | 32 | 12 | 61.1 | |||||
22– (strongly positive) | 28 | 13 | 53.1 | |||||
Not performed | 39 | 14 | 76.0 | |||||
Progesterone receptor(EIA), fmol/mg | ||||||||
<10 (negative) | 43 | 21 | 56.7 | 0.1221 | ||||
10–95 (Weakly positive) | 35 | 17 | 54.0 | |||||
96– (strongly positive) | 40 | 14 | 68.8 | |||||
Not performed | 42 | 15 | 75.0 | |||||
Negative/weakly positive | 78 | 38 | 55.2 | 0.0189 | 1 | |||
Strongly positive/Not performed | 82 | 29 | 71.9 | 0.679 | 0.361 | 1.274 | 0.2278 | |
Type of breast surgery | ||||||||
Breast conserving surgery (BCS) | 43 | 15 | 71.3 | 0.4737 | ||||
Mastectomy | 117 | 52 | 61.3 | |||||
Chemotherapy | ||||||||
Others, none | 68 | 23 | 72.9 | 1 | ||||
Anthracycline/Taxane/CMF | 92 | 44 | 56.8 | 0.0136 | 0.714 | 0.342 | 1.489 | 0.3689 |
Hormone therapy | ||||||||
Ovarian Function Suppression ± Others | 18 | 5 | 67.3 | 0.6537 | ||||
Selective estrogen receptor modulators | 36 | 15 | 59.5 | |||||
Others, none | 106 | 47 | 64.2 | |||||
Radiation therapy (RT) | ||||||||
Not performed | 131 | 54 | 65.6 | 0.2767 | ||||
Performed | 29 | 13 | 53.7 | |||||
Age at surgery | ||||||||
Case (younger than 30) | 80 | 37 | 61.7 | 0.3865 | 0.557 | 0.251 | 1.239 | 0.1515 |
Control (elder counterpart) | 80 | 30 | 65.6 | 1 | ||||